Appendix AD8.7
Summary of Serious Adverse Events Occurring in
Protocol 212 Considered to be Unlikely to be Related to Bupropion
Sustained-Release
|
Patient # |
Age |
Gender |
Dose (mg/d) |
Duration (days) |
Adverse Event |
|
20128 |
51 |
M |
Placebo |
1 |
Excision of pre-existing basal cell carcinoma |
|
11033 |
37 |
F |
300 |
Prolonged |
Cervical carcinoma in situ |
|
50376 |
36 |
F |
150 |
1 |
Excision of pre-existing basal cell carcinoma and
benign intradermal nevus |
|
40540 |
31 |
F |
300 |
1 |
Spontaneous abortion eight days after
discontinuation from study |
Back a Page
Next Section - Statistical Review
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index